{
    "clinical_study": {
        "@rank": "30108", 
        "acronym": "Triple-B", 
        "arm_group": [
            {
                "arm_group_label": "Carbo/cyclo", 
                "arm_group_type": "Active Comparator", 
                "description": "Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks"
            }, 
            {
                "arm_group_label": "Carbo/cyclo + Bevacizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Bevacizumab 10 mg/kg d1, 15 Q 4 weeks"
            }, 
            {
                "arm_group_label": "Paclitaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks"
            }, 
            {
                "arm_group_label": "Paclitaxel + bevacizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Paclitaxel 90 mg/m2 d1, 8, 15 Bevacizumab 10 mg/kg d1, 15 Q 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor\n      survival. TNBC can be divided into at least two molecular entities; BRCA-like and\n      non-BRCA-like. In this trial we would like to investigate whether a molecular subgroup\n      exists within TNBCs that derives a benefit from bevacizumab added to first line\n      chemotherapy."
        }, 
        "brief_title": "Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "December 2029", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In preclinical studies the addition of bevacizumab to chemotherapy improves drug access in\n      the tumor. In humans, bevacizumab monotherapy normalizes the tumor vascularization. It is\n      presently unknown what molecular subtype would derive a progression free survival (PFS)\n      benefit of the addition of bevacizumab to first line chemotherapy. There are indications\n      that patients with high VEFGA and/or VEFGR-2 plasma levels derive most benefit.\n\n      There are indications that TNBC that are BRCA-like are more sensitive to bifunctional\n      alkylating and platinum agents than non-BRCA-like TNBCs, and relatively resistant to\n      taxanes. Consequently, because TNBCs in general derive substantial benefit from taxanes, we\n      anticipate that non-BRCA-like TNBCs are exquisitely sensitive to taxanes. Bevacizumab and\n      paclitaxel are synergistic in preclinical models. Therefore we anticipate that bevacizumab\n      added to paclitaxel confers a substantial progression-free survival benefit in non-BRCA-like\n      patients. We would like to test these hypotheses in a prospective clinical trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed triple negative breast cancer\n\n          -  Histological confirmation of triple negative breast cancer of a metastatic lesion is\n             recommended\n\n          -  Histological or cytological confirmation of metastatic breast cancer is required in\n             case of normal CA 15.3 levels\n\n          -  No previous cytotoxic therapy for metastatic disease\n\n          -  Disease-free interval of at least 12 months after completion of adjuvant taxane\n             and/or platinum compound therapy\n\n          -  Measurable disease according to RECIST\n\n          -  Informative sVEGFR2 level test result in plasma baseline samples (taken before\n             treatment started)\n\n          -  Informative BRCA-like test result on primary tumor or metastasis (up to 5% of\n             patients with an unknown test result will be randomized)\n\n          -  WHO performance status of 0 or 1\n\n          -  Adequate bone marrow function: neutrophils \u2265 1.5 x 10E9 cells/l, platelets \u2265100 x\n             10E9 cells/l, Hb \u2265 6.2 mmol/l.\n\n          -  Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN);\n             alkaline phosphatase < 2.5 x ULN (< 5 x ULN in case of liver metastases, and < 7 x\n             ULN in case of bone metastases); transaminases (ASAT/ALAT) < 2.5 x ULN (and < 5 x ULN\n             in case of liver metastases).\n\n          -  Normal renal function:\n\n               -  calculated (Cockcroft-Gault) or measured creatinine clearance > 50 mL/min\n\n               -  Urine dipstick for proteinuria < 2+. Patients with > 2+ proteinuria on dipstick\n                  urinalysis at baseline should undergo 24-hours urine collection and must\n                  demonstrate \u22641 g of protein/24hr.\n\n          -  INR < 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for\n             at least two weeks with a low molecular weight heparin or coumarin, then an INR\n             within the target range (usually between 2 and 3) is allowed.\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Receptor conversion to hormone receptor positive (defined as >= 1% positive ER or PgR\n             tumor cells) or HER2 positive\n\n          -  Another cancer except basal-cell carcinoma of the skin or in situ cervical cancer\n             within the previous 5 years\n\n          -  Other antitumor therapy within the previous 21 days\n\n          -  Known CNS disease except for treated brain metastases.\n\n          -  Uncontrolled serious medical or psychiatric illness\n\n          -  Pre-existing peripheral neuropathy > grade 1  (NCI-CTC AE (version 4.03)) at\n             inclusion\n\n          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months of randomization\n\n          -  An infection requiring parenteral antibiotic\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             prior to randomization or anticipation of need for major surgical procedure during\n             the course of the study\n\n          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or\n             recent peripheral arterial thrombosis within 6 months prior to randomization)\n\n          -  Non healing wound or non healing fracture\n\n          -  Arterial or venous thrombosis \u2264 12 months prior to registration\n\n          -  Inadequate controlled hypertension (systolic > 140 mm Hg and/or diastolic  > 90 mm\n             Hg)\n\n          -  Prior history of hypertensive crisis or hypertensive encephalopathy\n\n          -  New York Heart Association Class II or greater congestive heart failure. LVEF by MUGA\n             or ultrasound must be \u2265 50% and should be performed within 4 weeks prior to\n             randomization if cardiac failure is suspected.\n\n          -  History of myocardial infarction or unstable angina within 6 months prior to\n             randomization\n\n          -  History of stroke or transient ischemic attack within 6 months prior to randomization\n\n          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of\n             therapeutic anticoagulation)\n\n          -  History of hemoptysis within 1 month prior to randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "304", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898117", 
            "org_study_id": "M13TNB", 
            "secondary_id": [
                "2013-001484-23", 
                "NL44403.031.13"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Carbo/cyclo", 
                "intervention_name": "Carbo/cyclo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Carboplatin", 
                    "Cyclophosphamide"
                ]
            }, 
            {
                "arm_group_label": "Carbo/cyclo + Bevacizumab", 
                "intervention_name": "Carbo/cyclo + bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Carboplatin", 
                    "Cyclophosphamide", 
                    "Bevazicumab"
                ]
            }, 
            {
                "arm_group_label": "Paclitaxel", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Paclitaxel"
            }, 
            {
                "arm_group_label": "Paclitaxel + bevacizumab", 
                "intervention_name": "Paclitaxel + Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paclitaxel", 
                    "evazicumab"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Triple negative", 
            "Metastatic"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "S Vrijaldenhoven, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Alkmaar", 
                        "country": "Netherlands", 
                        "zip": "1815 JD"
                    }, 
                    "name": "MCA"
                }, 
                "investigator": {
                    "last_name": "S Vrijaldenhoven, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "i.oving@zgt.nl", 
                    "last_name": "I M Oving, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Almelo", 
                        "country": "Netherlands", 
                        "zip": "7609 PP"
                    }, 
                    "name": "ZGT"
                }, 
                "investigator": {
                    "last_name": "I M Oving, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Netherlands Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Sabine C Linn, Prof. MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "m.konings@vumc.nl", 
                    "last_name": "I R Konings, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }, 
                    "name": "AZVU"
                }, 
                "investigator": {
                    "last_name": "I R Konings, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "s.dohmen@bovenij.nl", 
                    "last_name": "S E Dohmen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1034 CS"
                    }, 
                    "name": "BovenIJ"
                }, 
                "investigator": {
                    "last_name": "S E Dohmen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "M.Troost@lievensberg.nl", 
                    "last_name": "M M Troost, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bergen op Zoom", 
                        "country": "Netherlands", 
                        "zip": "4624 VT"
                    }, 
                    "name": "Lievensberg ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "M M Troost, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rrietbroek@rkz.nl", 
                    "last_name": "R C Rietbroek, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Beverwijk", 
                        "country": "Netherlands", 
                        "zip": "1940 EB"
                    }, 
                    "name": "Rode Kruis Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "R C Rietbroek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "D F Kehrer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Capelle aan de IJssel", 
                        "country": "Netherlands", 
                        "zip": "2906 ZC"
                    }, 
                    "name": "IJsselland ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "D F Kehrer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "j.portielje@hagaziekenhuis.nl", 
                    "last_name": "J E Portielje, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Den Haag", 
                        "country": "Netherlands", 
                        "zip": "2545 CH"
                    }, 
                    "name": "Haga"
                }, 
                "investigator": {
                    "last_name": "J E Portielje, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "imholza@dz.nl", 
                    "last_name": "A L Imholz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Deventer", 
                        "country": "Netherlands", 
                        "zip": "7416 SE"
                    }, 
                    "name": "Deventer ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "A L Imholz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "s.hovenga@nijsmellinghe.nl", 
                    "last_name": "S Hovenga, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Drachten", 
                        "country": "Netherlands", 
                        "zip": "9202 NN"
                    }, 
                    "name": "Nijsmellinghe"
                }, 
                "investigator": {
                    "last_name": "S Hovenga, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "haringhuizena@zgv.nl", 
                    "last_name": "A W Haringhuizen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ede", 
                        "country": "Netherlands", 
                        "zip": "6716 RP"
                    }, 
                    "name": "Ziekenhuis Gelderse Vallei"
                }, 
                "investigator": {
                    "last_name": "A W Haringhuizen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "M W Dercksen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands", 
                        "zip": "5631 BM"
                    }, 
                    "name": "Maxima Medisch Centrum"
                }, 
                "investigator": {
                    "last_name": "M W Dercksen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bea.tanis@ghz.nl", 
                    "last_name": "B C Tanis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Gouda", 
                        "country": "Netherlands", 
                        "zip": "2803 HH"
                    }, 
                    "name": "Groene Hart"
                }, 
                "investigator": {
                    "last_name": "B C Tanis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bdevalk@spaarneziekenhuis.nl", 
                    "last_name": "B de Valk, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hoofddorp", 
                        "country": "Netherlands", 
                        "zip": "2134 TM"
                    }, 
                    "name": "Spaarne ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "B de Valk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "graafhi@znb.nl", 
                    "last_name": "H de Graaf, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeuwarden", 
                        "country": "Netherlands", 
                        "zip": "8934 AD"
                    }, 
                    "name": "MCL"
                }, 
                "investigator": {
                    "last_name": "H de Graaf, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "j.r.kroep@lumc.nl", 
                    "last_name": "J R Kroep, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2333 ZA"
                    }, 
                    "name": "LUMC"
                }, 
                "investigator": {
                    "last_name": "J R Kroep, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "h.oosterkamp@mchaaglanden.nl", 
                    "last_name": "H M Oosterkamp, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leidschendam", 
                        "country": "Netherlands", 
                        "zip": "2262 BA"
                    }, 
                    "name": "MCH"
                }, 
                "investigator": {
                    "last_name": "H M Oosterkamp, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fe.de.jongh@ikazia.nl", 
                    "last_name": "F E de Jong, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3083 AN"
                    }, 
                    "name": "Ikazia"
                }, 
                "investigator": {
                    "last_name": "F E de Jong, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "p.hamberg@sfg.nl", 
                    "last_name": "A P Hamberg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3045 PM"
                    }, 
                    "name": "St. Fransicus Gasthuis"
                }, 
                "investigator": {
                    "last_name": "A P Hamberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Q C van Rossum-Schornagel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Schiedam", 
                        "country": "Netherlands", 
                        "zip": "3118 JH"
                    }, 
                    "name": "Vlietland ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "Q C van Rossum-Schornagel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jmgriel@elisabeth.nl", 
                    "last_name": "J M van Riel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tilburg", 
                        "country": "Netherlands", 
                        "zip": "5022 GC"
                    }, 
                    "name": "St. Elisabeth"
                }, 
                "investigator": {
                    "last_name": "J M van Riel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hroerdink@tsz.nl", 
                    "last_name": "H Th Roerdink, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tilburg", 
                        "country": "Netherlands", 
                        "zip": "5042 AD"
                    }, 
                    "name": "Tweesteden ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "H Th Roerdink, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "a.h.honkoop@isala.nl", 
                    "last_name": "A H. Honkoop, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands", 
                        "zip": "8025 AB"
                    }, 
                    "name": "Isala Klinieken"
                }, 
                "investigator": {
                    "last_name": "A H Honkoop, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "4", 
        "official_title": "Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer", 
        "overall_contact": {
            "email": "s.linn@nki.nl", 
            "last_name": "Sabine C Linn, Prof. MD", 
            "phone": "+3120512", 
            "phone_ext": "2870"
        }, 
        "overall_contact_backup": {
            "email": "i.mandjes@nki.nl", 
            "last_name": "Ingrid A. Mandjes, MSc", 
            "phone": "+3120512", 
            "phone_ext": "2667"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Prospectively analyze whether VEGFR2 plasma levels at baseline predict for differential progression-free survival (PFS) benefit of bevacizumab added to first line palliative chemotherapy in triple-negative breast cancer (TNBC)", 
                "measure": "Determine PFS in the different VEGFR2 levels", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to 120 months"
            }, 
            {
                "description": "Validate the BRCA-like test in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC", 
                "measure": "Validate the BRCA-like test", 
                "safety_issue": "No", 
                "time_frame": "assessed up to 120 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Validate that bevacizumab added to first line palliative chemotherapy improves PFS in TNBC", 
                "measure": "Improvement of PFS by adding bevacicumab", 
                "safety_issue": "No", 
                "time_frame": "assessed up to 120 months"
            }, 
            {
                "description": "Define predictive biomarkers for PFS gain of the addition of bevacizumab to first line chemotherapy; test VEGFA amplification vs no amplification and PFS stratified by chemotherapy regimen.", 
                "measure": "Define predictive biomarkers for PFS gain", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months"
            }, 
            {
                "description": "etermine PFS regarding the efficacy of the two different first line chemotherapeutic regimens, regardless of bevacizumab yes or no, in the whole study group, and in the BRCA-like and non-BRCA-like TNBCs subgroups separately", 
                "measure": "Determine PFS", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until dat of first documented progression or date of death, which ever comes first, assessed up to 120 months"
            }, 
            {
                "description": "Evaluation of overall survival (OS) for all (sub)group comparisons as pre-specified for PFS", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "assessed up to 120 months"
            }, 
            {
                "description": "Adverse events will be graded according to  NCI Common Toxicity Criteria version 4.03", 
                "measure": "Toxicity of all study regimens", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed  at 1 year"
            }
        ], 
        "source": "The Netherlands Cancer Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Borstkanker Onderzoek Groep", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Roche Pharma AG", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "The Netherlands Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}